title: The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
abstract: Both Congestive Heart Failure (CHF) and Chronic Renal Failure (CRF) are increasing steadily in the community. We propose that there is a vicious circle established whereby CHF and CRF both cause anemia and the anemia then worsens both the CHF and CRF causing more anemia and so on. We call this the Cardio Renal Anemia (CRA) syndrome. By the combination of active treatment of the CHF and control of the anemia with subcutaneous erythropoietin and intravenous iron, the progression of both the CHF and the CRF can be slowed or stopped in most cases, the quality of life improved and the need for recurrent hospitalization reduced. This will involve cooperation between internists, cardiologists, and nephrologists to allow early and maximal therapy of both the CHF and the anemia.
authors.affiliation: Department of Nephrology and Cardiology, Tel Aviv Medical Center, Israel. donald@netvision.net.il
authors.forename: D S
authors.initials: DS
authors.lastname: Silverberg
authors.forename: D
authors.initials: D
authors.lastname: Wexler
authors.forename: M
authors.initials: M
authors.lastname: Blum
authors.forename: J
authors.initials: J
authors.lastname: Tchebiner
authors.forename: D
authors.initials: D
authors.lastname: Sheps
authors.forename: G
authors.initials: G
authors.lastname: Keren
authors.forename: D
authors.initials: D
authors.lastname: Schwartz
authors.forename: R
authors.initials: R
authors.lastname: Baruch
authors.forename: T
authors.initials: T
authors.lastname: Yachnin
authors.forename: M
authors.initials: M
authors.lastname: Shaked
authors.forename: A
authors.initials: A
authors.lastname: Zubkov
authors.forename: S
authors.initials: S
authors.lastname: Steinbruch
authors.forename: A
authors.initials: A
authors.lastname: Iaina
mesh_terms: D000368:Aged; D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D006760:Hospitalization; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D010101:Oxygen Consumption; D011994:Recombinant Proteins; D013318:Stroke Volume
chemical_list: D005290:Ferric Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid